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LETTERS TO THE EDITOR
A Four-Year-Old Rabbit Cannot
Be Considered the Right Model
for Investigating Cardiac Senescence
Przyklenk et al. (1) have recently shown that cardioprotection with
ischemic preconditioning (PC) is preserved in the senescent heart.
The investigators found no differences in infarct size reduction by
PC among adult (4 to 6 months), middle aged (2 years) and old
(4 years) rabbits (1). Reduction of infarct size on “in vivo” rabbits
may be considered an appropriate experimental model to study
ischemic PC in animals. However, when considered in cardiac
aging, serious concerns arise about the experimental model in-
volved in their study. Indeed, animal models are used in aging
research to overcome the limitation of studying aging in humans
(e.g., the relatively long life span of humans). Because most aspects
of aging in rodents are similar to human aging despite their short
life span, rats and mice have been used extensively to study the
pathophysiology of aging (2).
In contrast, data on the senescent rabbit are not available
because of its relative long life span. In fact, the maximum life span
potential (MLSP) for rabbits is 13 years (3,4); thus, if we
optimistically consider MLSP for humans as 100 years, a 4-year-
old rabbit cannot be considered a good model of the aging heart.
A 4-year-old rabbit could be compared to a 30-year-old human
and obviously a 6-month-old rabbit to 4-year-old human.
Accordingly, morphologic markers of cardiovascular aging are
qualitatively but not quantitatively similar to that observed in
well-studied models of aging. Przyklenk et al. (1) showed that
mean myocyte cross-sectional area increased from 397 7 m2 in
adult to 445  11 m2 in middle aged (12%) and to 506 
10 m2 in old (27%) rabbits. In addition, the investigators also
claimed that myocardial collagen content increased from 6.2 
0.3% in adult versus 10.8 0.5% in old rabbit heart. In both cases,
these age-related modifications are significantly smaller than that
found by Anversa et al. (5), who demonstrated that myocyte cell
volume increases up to 60% from adult to senescent rat hearts
while collagen content increases from 7% in adult to 22% in
senescent rat hearts. The modifications showed by Przyklenk et al.
(1) are approximately half of those expected from a validated model
of the aging heart.
Conversely, reduction of ischemic PC mechanism has been well
established in a 24-month-old rat model (6–9) that proportionally
represents a human being of age 60 (rat MLSP  3.5 years) (2).
Moreover, Przyklenk et al. (1) also showed a slight reduction of
ischemic PC efficacy in two-year and three- to five-year versus
four- to six-month-old rabbit (15%). This is in agreement with
the concept that pathophysiologic modifications that occur during
aging are not “on–off ” and that ischemic PC might have a
progressive decline with aging. Infarct size progressively increases
in the preconditioned rat heart (9) from 15% in adult animals (3
months), to 25% in middle-aged (12 months) and to 40% in
old animals (20 months). Accordingly, as most of the age-related
pathophysiologic modifications were observed in the senescent rat
and human heart, ischemic PC was restored or preserved by
antiaging interventions such as exercise training (10,11). On the
basis of this evidence, ischemic PC efficacy should be significantly
reduced also in 7- to 8-year-old rabbits that probably represent the
24-month-rat and 60-year-old human homologues of cardiac
senescence.
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REPLY
We thank Dr. Abete and colleagues for their interest in our work
(1) and for their query of whether the rabbit is the “right” model
to assess the efficacy of ischemic preconditioning (PC) in aging
animals.
The rabbit has not been extensively utilized in aging studies.
Indeed, there is even controversy as to the maximum life span of
the rabbit, with values of 7 years (2,3) versus 13 years (cited by
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Abete et al.) having been reported. This variation in life span is not
unique to the rabbit, and it underscores a crucial caveat: life span
or age is, in itself, a poor predictor of the aging process (4). Thus,
evaluation of established biomarkers of aging (4)—rather than
attempts to equate, from maximum life spans, relative ages among
species—may represent a more germane approach in addressing
this question.
We observed significant myocyte hypertrophy and myocardial
fibrosis—the morphologic hallmarks of cardiovascular aging—in
four-year-old versus young adult rabbits (1). For example, left
ventricular collagen content was 10.8  0.5% (SD 1.8%) versus
6.2  0.3% (SD 1.2%), respectively—a mean 1.7-fold increase
(range: 1.2- to 2.5-fold, computed from the SD values) in fibrosis.
Abete and colleagues contend that our results are qualitatively, but
not quantitatively, similar to those observed in the2-year-old rat,
an accepted model of senescence. We find, however, that despite
methodologic differences among studies, our results fall within the
range of data reported for rats (5,6)—including those from
Anversa et al. (5), in which collagen volume fraction was 16  4%
(mean  SD) versus 8  2% in 29- versus 4-month-old animals,
corresponding to a twofold increase (range: 1.2- to 3.3-fold) in
fibrosis. (Of note, the values of 7% and 22% cited by Abete et al.
were obtained in the right, rather than the left, ventricle (5)). With
regard to hypertrophy, our 1.3-fold increase in myocyte cross-
sectional area compares favorably with the 1.4-fold increase
seen in 23-month-old versus 7-month-old rats (6), and, inter-
estingly, with human autopsy data (death unrelated to cardio-
vascular disease) showing, via regression analysis, a 1.3-fold
increase in myocyte volume between 20 and 75 years of age (7).
Finally, the four-year-old rabbits displayed a third, functional
hallmark of cardiovascular aging—loss of responsiveness to
beta-adrenergic stimulation (1).
There is an emerging consensus that, in isolated buffer-perfused
rat heart, the efficacy of infarct size reduction with PC wanes with
increasing age (8,9). In contrast—and contrary to the correspon-
dents’ interpretation of our data—we found sustained, 49%, 58%
and 50% reductions of infarct size in PC rabbits versus age-
matched adult, two-year-old and four-year-old controls (1). Does
this difference in outcome make the four-year-old rabbit, exhibit-
ing definitive biomarkers of cardiovascular aging, the “wrong”
model? We believe this disparity is not a question of “right” versus
“wrong” models. Indeed, recent preliminary evidence from isolated
human myocardial samples—arguably a “right” model—revealed
persistent PC-induced protection even in cohorts aged 70 to 90
years old (10). Rather, this may reflect underlying mechanistic
difference(s) among models/species that warrant resolution.
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Revascularizing Chronic Total Occlusions:
What About the Coronary
Collaterals and Myocardial Viability Story?
With reference to the study by Suero et al. (1), I wish to make the
following comments:
1. Although there was a 10-year survival advantage in patients
who had a successful percutaneous coronary intervention (PCI) to
a chronic total occlusion (CTO), this study did not look at the
relation of such a survival advantage following a successful revas-
cularization to the presence of viability of infarcted myocardium in
the 54% with a previous myocardial infarction (MI). This rela-
tionship is expected.
2. It may not be correct to state that all CTOs benefit from
revascularization. I suspect that the survival advantage in this
cohort came mainly from improvement in left ventricular (LV)
function following improvement in contractility of viable infarcted
myocardial segments (2). In support, there is data from some
uncontrolled surgical series to show that improved survival in
patients with LV dysfunction correlates with the presence of
myocardial viability in several LV segments (3).
This will be the subject of evaluation in the Total Occlusion
Study of Canada (TOSCA-2) substudy of the ongoing Occluded
Artery Trial (OAT), which follows the previously published
TOSCA study (4). Interestingly, this survival advantage occurred
although only 10% of patients received a stent. A significant
reduction in restenosis following stenting compared with balloon
angioplasty of a CTO was reported in the TOSCA study.
3. The role of collaterals in this situation has always been an area
both of controversy and interest. This would perhaps be a good
opportunity to review the data to see whether the survival advan-
tage reported in this study correlates with the presence of angio-
graphic collaterals, especially as there is now data to show that
collateral flow assessed invasively (5) does correlate with viability of
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